Research programme: site specific immunomodulators - Qu BiologicsAlternative Names: QBECP; QBSAU; SSI - Qu Biologics
Latest Information Update: 02 Oct 2015
At a glance
- Originator Qu Biologics
- Developer Geisel School of Medicine; McMaster University; Qu Biologics
- Class Bacterial antigens; Cancer vaccines
- Mechanism of Action Immunomodulators; Macrophage modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Crohn's disease; Inflammation; Inflammatory bowel diseases; Lung cancer; Malignant melanoma; Rheumatoid arthritis